The Preston Robert Tisch Brain Tumor Center at Duke University
Welcome,         Profile    Billing    Logout  
 13 Trials 
25 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Peters, Katherine B
GBM AGILE, NCT03970447 / 2020-002250-24: A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Calendar Jan 2030 - Dec 2030: Market entry for glioblastoma
Oct 2023 - Dec 2023: Top-line data from GBM AGILE trial for glioblastoma
Recruiting
2/3
1030
Europe, Canada, US, RoW
Temozolomide, Temodar, Temodal, Temcad, Lomustine, CCNU, CeeNU, Gleostine, Regorafenib, Stivarga, BAY 73-4506, Radiation, Paxalisib, GDC-0084, VAL-083, Dianhydrogalactitol, VT1021, Troriluzole, BHV-4157, ADI-PEG 20, Pegargiminase
Global Coalition for Adaptive Research, Bayer, Kazia Therapeutics Limited, Kintara Therapeutics, Inc., Biohaven Pharmaceuticals, Inc., Vigeo Therapeutics, Inc., Polaris Group
Glioblastoma
06/26
06/28
BMX-HGG, NCT02655601: Trial of Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide and BMX-001

Active, not recruiting
2
160
US
BMX-001, manganese butoxyethyl pyridyl porphyrin, Radiation Therapy, Temozolomide, TMZ
BioMimetix JV, LLC, Duke Cancer Institute, National Cancer Institute (NCI)
High Grade Glioma, Astrocytoma, Grade III, Glioblastoma
08/23
12/24
PROSPECT, NCT04947319: Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma ( Study)

Recruiting
2
112
US
Tirabrutinib, ONO-4059
Ono Pharmaceutical Co. Ltd
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
03/27
03/27
DIET2TREAT, NCT05708352: A Phase 2 Study of the Ketogenic Diet Vs Standard Anti-cancer Diet Guidance for Patients with Glioblastoma in Combination with Standard-of-care Treatment

Recruiting
2
170
US
Keto Diet, Standard Anti-Cancer Diet
Cedars-Sinai Medical Center, National Cancer Institute (NCI)
Glioblastoma Multiforme
06/28
06/29
ATTAC, NCT00639639: Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme

Completed
1
42
US
tetanus toxoid, therapeutic autologous dendritic cells, therapeutic autologous lymphocytes
Gary Archer Ph.D., National Cancer Institute (NCI)
Malignant Neoplasms of Brain
04/17
06/22
RESIST, NCT02193347: IDH1 Peptide Vaccine for Recurrent Grade II Glioma

Completed
1
24
US
PEPIDH1M vaccine, Tetanus-Diphtheria Toxoid (Td), Tenivac, Temozolomide, Temodar
Katy Peters, MD, PhD
Brain Cancer, Brain Neoplasm, Primary, Brain Neoplasms, Recurrent, Brain Tumor, Cancer of the Brain
02/20
02/20
NCT05023551: Study of DSP-0390 in Patients with Recurrent High-Grade Glioma

Active, not recruiting
1
39
Japan, US
DSP-0390
Sumitomo Pharma America, Inc.
High Grade Glioma, Glioblastoma Multiforme
09/26
10/26
ViCToRy, NCT05609994: Vorasidenib in Combination with Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas

Not yet recruiting
1
48
US
PEPIDH1M vaccine + vorasidenib
Katy Peters, MD, PhD, Servier
Low Grade Glioma of Brain
08/27
08/29
SPiRiT, NCT04567251: Survivorship Study of Cancer Patients Who Received Cranial Radiation Therapy

Terminated
N/A
5
US
Namzaric®, Placebo
Duke University, Varian Medical Systems
Brain Metastases, Adult, Primary Brain Tumor, Lung Cancer
05/24
05/24
NCT06648473: Repeatability of Magnetic Resonance Imaging in Patients With IDH1 Mutant Glioma on Ivosidenib

Not yet recruiting
N/A
40
US
MRI Scan
Duke University, Institut de Recherches Internationales Servier
Low Grade Glioma of Brain
12/25
12/25
Khasraw, Mustafa
NCT04762069 / 2021-003659-40: A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

Hourglass Jan 2023 - Jun 2023 : Data from trial for glioblastoma
Hourglass Jul 2022 - Dec 2022 : Interim analysis data from trial for glioblastoma in adults
Active, not recruiting
2
210
Europe, US
Berubicin, Berubicin Hydrochloride, Lomustine, Lomustine Capsules, CCNU, CeeNU, Gleostine
CNS Pharmaceuticals, Inc., Worldwide Clinical Trials
Glioblastoma Multiforme, Adult
12/24
03/25
NUTMEG, NCT04195139 / ACTRN12617000267358: Nivolumab and Temozolomide Versus Temozolomide Alone in Newly Diagnosed Elderly Patients With GBM

Active, not recruiting
2
103
US, RoW
Nivolumab, Opdivo, Temozolomide, Temodar, Temodal, Temcad
University of Sydney, Cooperative Trials Group for Neuro-Oncology
Glioblastoma Multiforme
06/24
12/25
PARAMETer, NCT05620914: A Window of Opportunity Study of Patritumab Deruxtecan in Patients with Brain Metastases

Not yet recruiting
2
15
US
Patritumab deruxtecan
Mustafa Khasraw, MBChB, MD, FRCP, FRACP, Daiichi Sankyo
Brain Metastases, Adult
04/26
04/27
MOAB, NCT06069726: A Multicenter Trial to Identify Optimal Atezolizumab Biomarkers in the Setting of Recurrent Glioblastoma. The Trial

Recruiting
2
80
US
Atezolizumab
Duke University
Recurrent Glioblastoma
01/26
01/27
NCT05303519: Safusidenib Phase 2 Study in IDH1 Mutant Glioma

Active, not recruiting
2
95
US
safusidenib, DS-1001b, AB-218
Nuvation Bio Inc., AnHeart Therapeutics Inc.
Glioma
03/27
07/27
NCT05634707: Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Recruiting
1
30
US
Fluoxetine, Temozolomide
Duke University
Primary Brain Tumor, Brain Tumor, Recurrent
12/26
06/27
PuMP, NCT06126744: Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of the Oncolytic HSV1 MVR-C5252

Recruiting
1
51
US
MVR-C5252
Duke University
Recurrent High Grade Glioma
12/26
12/27
BRiTE, NCT04903795: Bispecific T Cell Engager for Patients With Grade IV Malignant Glioma

Not yet recruiting
1
18
US
hEGFRvIII-CD3 (BRiTE), BRiTE
Duke University
Malignant Glioma, Glioblastoma
12/26
12/26
ETAPA I, NCT05283109: Peptide-based Tumor Associated Antigen Vaccine in GBM

Recruiting
1
36
US
Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, P30-EPS, Hiltonol, poly-ICLC
Mustafa Khasraw, MBChB, MD, FRCP, FRACP, National Cancer Institute (NCI)
Glioma, Malignant
04/25
02/28
NCT04937413: The PCSK9i Inhibitor Evolocumab - a Surgical Trial of Pharamcodynamics and Kinetics Evaluation

Completed
1
32
US
Evolocumab, Repatha
Duke University
Malignant Glioma, Glioblastoma
09/23
10/23
NCT05695976: GRETeL: Tumor Response to Standard Radiotherapy and TMZ Patients With GBM

Suspended
N/A
100
US
Duke University, Personalis Inc.
Glioblastoma, Glioma, Malignant
01/29
01/29
Kallas, Keith
ENGOT-EN20, NCT05611931 / 2022-002540-42: Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma

Jul 2024 - Dec 2024: Top-line data from XPORT-EC trial in participants with TP53 wild type endometrial cancer
Recruiting
3
220
Europe, Canada, US, RoW
Selinexor, KPT-330, Matching Placebo for selinexor
Karyopharm Therapeutics Inc, GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Belgium and Luxembourg Gynaecological Oncology Group, North Eastern German Society of Gynaecological Oncology, Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies, Spanish Research Group in Ovarian Cancer, The Central and Eastern European Gynecologic Oncology Group, Israeli Society of Gynecologic Oncology, Australia New Zealand Gynaecological Oncology Group
Endometrial Cancer
01/25
01/28
REFRaME-O1, NCT05870748: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Recruiting
2/3
600
Canada, US, RoW
Luveltamab tazevibulin, STRO-002, Luvelta, Pegfilgrastim, Neulasta, Gemcitabine, Paclitaxel, Pegylated liposomal doxorubicin, Topotecan
Sutro Biopharma, Inc., GOG Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT), Asia-Pacific Gynecologic Oncology Trials Group (APGOT)
Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Platinum-resistant Ovarian Cancer
08/27
02/28
SRF388-201, NCT05359861: Trial of Atezolizumab and Bevacizumab With SRF388 or Placebo in Patients With Hepatocellular Carcinoma

Active, not recruiting
2
134
US, RoW
SRF388, Atezolizumab, Tecentriq, Bevacizumab, Avastin, Placebo
Coherus Biosciences, Inc.
Hepatocellular Carcinoma
05/25
05/26
NCT05634707: Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Recruiting
1
30
US
Fluoxetine, Temozolomide
Duke University
Primary Brain Tumor, Brain Tumor, Recurrent
12/26
06/27

Download Options